T1	intervention 79 101	lipegfilgrastim (XM22)
T2	total-participants 439 442	208
T3	eligibility 443 470	chemotherapy-naive patients
T7	outcome 894 902	mean DSN
T4	control 537 550	pegfilgrastim
T5	outcome-Measure 749 796	duration of severe neutropenia (DSN) in cycle 1
T6	outcome 856 870	DSN in cycle 1
T9	iv-cont-mean 907 916	0.76 days
T10	cv-cont-mean 957 966	0.87 days
T8	outcome 1140 1180	absolute neutrophil count (ANC) at nadir
T11	outcome 1190 1207	ANC recovery time
T12	outcome 1223 1254	safety and tolerability profile
